PMID- 37418933
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230901
IS  - 2772-9508 (Electronic)
IS  - 2772-9508 (Linking)
VI  - 153
DP  - 2023 Oct
TI  - Myricetin encapsulated chitosan nanoformulation for management of type 2 
      diabetes: Preparation, optimization, characterization and in vivo activity.
PG  - 213542
LID - S2772-9508(23)00265-0 [pii]
LID - 10.1016/j.bioadv.2023.213542 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a serious and alarming disease attracting 
      widespread attention. It is not a single metabolic disease; over time, it leads 
      to serious disorders, namely, diabetic nephropathy, neuropathy, retinopathy and 
      several cardiovascular, hepatocellular complications. The increase in T2DM cases 
      in recent times has attracted significant attention. Currently, the medications 
      available have side effects, and injectables are painful, causing trauma to the 
      patients. Therefore, it is imperative to come up with oral delivery. In this 
      background we report here a nanoformulation carrying natural small molecule 
      Myricetin (MYR) encapsulated within Chitosan nanoparticles (CHT-NPs). MYR-CHT-NPs 
      were prepared by ionic gelation method and evaluated using different 
      characterization techniques. The in vitro release of MYR from CHT NPs in 
      different physiological media showed pH dependence. in vivo pharmacodynamic study 
      followed by oral administration in Albino Wistar rats showed better glycaemic 
      control than existing drug. Further, the optimized nanoparticles also exhibited 
      controlled increase in weight as compared to Metformin. The biochemistry profile 
      of rats treated with nanoformulation reduced the levels of several pathological 
      biomarkers, indicating additional benefits of MYR. Histopathological images 
      exhibited no toxicity or changes in the major organs section in contrast to 
      normal control, suggesting safe oral administration of the encapsulated MYR. 
      Thus, we conclude that MYR-CHT-NPs represent an attractive delivery vehicle in 
      improving the blood glucose level with controlled weight and have the potential 
      to be safely administered orally for the management of T2DM.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Upadhyay, Mansi
AU  - Upadhyay M
AD  - Department of Biosciences & Bioengineering, Indian Institute of Technology 
      Bombay, Mumbai 400076, India. Electronic address: mansiupadhyay14@gmail.com.
FAU - Hosur, Ramakrishna V
AU  - Hosur RV
AD  - Department of Biosciences & Bioengineering, Indian Institute of Technology 
      Bombay, Mumbai 400076, India.
FAU - Jha, Abhishek
AU  - Jha A
AD  - Department of Pharmaceutical Engineering & Technology, Indian Institute of 
      Technology (BHU) Varanasi, 221005, India.
FAU - Bharti, Kanchan
AU  - Bharti K
AD  - Department of Pharmaceutical Engineering & Technology, Indian Institute of 
      Technology (BHU) Varanasi, 221005, India.
FAU - Mali, Pramod S
AU  - Mali PS
AD  - Department of Biosciences & Bioengineering, Indian Institute of Technology 
      Bombay, Mumbai 400076, India.
FAU - Jha, Akash Kumar
AU  - Jha AK
AD  - Department of Biosciences & Bioengineering, Indian Institute of Technology 
      Bombay, Mumbai 400076, India.
FAU - Mishra, Brahmeshwar
AU  - Mishra B
AD  - Department of Pharmaceutical Engineering & Technology, Indian Institute of 
      Technology (BHU) Varanasi, 221005, India.
FAU - Kumar, Ashutosh
AU  - Kumar A
AD  - Department of Biosciences & Bioengineering, Indian Institute of Technology 
      Bombay, Mumbai 400076, India. Electronic address: ashutoshk@iitb.ac.in.
LA  - eng
PT  - Journal Article
DEP - 20230630
PL  - Netherlands
TA  - Biomater Adv
JT  - Biomaterials advances
JID - 9918383886206676
RN  - 9012-76-4 (Chitosan)
RN  - 76XC01FTOJ (myricetin)
RN  - 0 (Flavonoids)
SB  - IM
MH  - Rats
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Chitosan/chemistry
MH  - Flavonoids/pharmacology/therapeutic use
MH  - *Nanoparticles/chemistry
MH  - Rats, Wistar
OTO - NOTNLM
OT  - Controlled weight
OT  - Flavonoid
OT  - Hypoglycaemic
OT  - Myricetin
OT  - Nanoparticles
OT  - Type 2 diabetes
COIS- Declaration of competing interest The authors assure no conflict of interest.
EDAT- 2023/07/08 10:42
MHDA- 2023/09/01 06:42
CRDT- 2023/07/07 18:05
PHST- 2023/04/11 00:00 [received]
PHST- 2023/06/27 00:00 [revised]
PHST- 2023/06/29 00:00 [accepted]
PHST- 2023/09/01 06:42 [medline]
PHST- 2023/07/08 10:42 [pubmed]
PHST- 2023/07/07 18:05 [entrez]
AID - S2772-9508(23)00265-0 [pii]
AID - 10.1016/j.bioadv.2023.213542 [doi]
PST - ppublish
SO  - Biomater Adv. 2023 Oct;153:213542. doi: 10.1016/j.bioadv.2023.213542. Epub 2023 
      Jun 30.